Verona Pharma (VRNA) announced its shareholders have approved the proposal for Merck (MRK) to acquire the company for $107 per ADS, for a total transaction value of approximately $10B. The transaction is being implemented by a scheme of arrangement under English law and remains subject to the sanction of the High Court of Justice of England and Wales. The court hearing to sanction the scheme has been scheduled for October 6.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA: